a public good project by the
Synthesis
Company
of California

© 2026

Cécile Bertho-Ruault | doi.page

0 works0 citations0 h-index

Google Scholar OpenAlex

Cécile Bertho-Ruault

GlaxoSmithKline (United Kingdom)(GB)

Research Areas

Liver physiology and pathology, Chronic Myeloid Leukemia Treatments, TGF-β signaling in diseases

Most-Cited Works

→ Discovery of 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor(2006)102 cited